O-Vax vaccine using dinitrophenyl-modified tumor cells from the patient: Phase II Update

Avax Technologies Inc. (AVXT), Kansas City,

Read the full 63 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE